Thu, Mar 30th, 2023
  • facebook
  • twitter
  • youtube
  • instagram
  • HOME
  • BUSINESS
  • POLITICS
  • ECONOMY
  • COUNTRIES
    • Caucasus
      • Armenia
      • Azerbaijan
      • Georgia
    • Central Asia
      • Kazakhstan
      • Kyrgyzstan
      • Tajikistan
      • Turkmenistan
      • Uzbekistan
    • Eastern Europe
      • Belarus
      • Moldova
      • Ukraine
    • Russia
  • OPINION
  • LIFESTYLE
  • FOCUS
The Tribune Logo
  • HOME
  • BUSINESS
  • POLITICS
  • ECONOMY
  • COUNTRIES
    • Caucasus
      • Armenia
      • Azerbaijan
      • Georgia
    • Central Asia
      • Kazakhstan
      • Kyrgyzstan
      • Tajikistan
      • Turkmenistan
      • Uzbekistan
    • Eastern Europe
      • Belarus
      • Moldova
      • Ukraine
    • Russia
  • OPINION
  • LIFESTYLE
  • FOCUS
Thu, Mar 30th, 2023
  • HOME
  • BUSINESS
  • POLITICS
  • ECONOMY
  • COUNTRIES
    • Caucasus
      • Armenia
      • Azerbaijan
      • Georgia
    • Central Asia
      • Kazakhstan
      • Kyrgyzstan
      • Tajikistan
      • Turkmenistan
      • Uzbekistan
    • Eastern Europe
      • Belarus
      • Moldova
      • Ukraine
    • Russia
  • OPINION
  • LIFESTYLE
  • FOCUS
  • HOME
  • BUSINESS
  • POLITICS
  • ECONOMY
  • COUNTRIES
    • Caucasus
      • Armenia
      • Azerbaijan
      • Georgia
    • Central Asia
      • Kazakhstan
      • Kyrgyzstan
      • Tajikistan
      • Turkmenistan
      • Uzbekistan
    • Eastern Europe
      • Belarus
      • Moldova
      • Ukraine
    • Russia
  • OPINION
  • LIFESTYLE
  • FOCUS
HEALTH
- World
The most promising coronavirus vaccine you’ve never heard of-POLITICO

(Read the full article on Politico.com)

Hopes are growing that a dark-horse coronavirus vaccine from a tiny U.S. drugmaker can shore up supplies in the U.S. and globally as safety concerns and production problems shadow shots from Johnson & Johnson and AstraZeneca, Politico reported.

According to Politico, the vaccine’s developer, Novavax, has never brought a product to market. The shot entered late-stage clinical trials months after candidates from bigger names like Pfizer and Moderna. But the Novavax vaccine proved just as potent as those mRNA shots in a U.K. trial, and the company is now preparing to file for U.S. authorization in a matter of weeks — potentially leapfrogging AstraZeneca, a former frontrunner.

Apr 28, 2021

DATA SNAPSHOT

BANKS
- Azerbaijan
Fitch affirms Azerbaijan’s Expressbank at ‘B’, outlook Stable
TRADE
- Uzbekistan
Uzbekistan’s foreign trade turnover at $13.15 bln in Q1, 2022
ECONOMY
- Belarus
Belarus inflation up 15.9% yr/yr in March-Statistics Committee
ECONOMY
- Georgia
Remittances to Georgia rise 3% yr/yr to $193 mln in March-central bank
THE TRIBUNE
- Eurasia
The Tribune suspends publication
HEALTH
- Covid-19
COVID-19 Eurasia Roundup
The Tribune keeps you up-to-date with the latest vaccines and infection data across the region.
OPINION
- Kazakhstan
OPINION-Kazakhstan’s Reforms Should Be More Than Just Show-FOREIGNPOLICY
  • facebook
  • twitter
  • youtube
  • instagram
  • Privacy Policy
  • Cookie Policy
  • About Us
  • Contact Us
NEWSLETTER

I have read the privacy policy and consent to the storage of my data in your archive.

© 2021 thetribune.com All rights reserved.